Return to Publications
January 2018
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.
Isaac Yi Kim, MD, PhD, MBA

$1M Grant Awarded to Rutgers Cancer Institute of New Jersey Prostate Cancer Researcher

A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia through a clinical trial. Study participants will receive chemo-hormonal therapy or therapy plus cytoreductive surgery that removes both the prostate and surrounding cancerous cells. Dr. Kim, an associate professor of surgery at Rutgers Robert Wood Johnson Medical School, will also measure quality-of-life outcomes.

Howard S. Hochster, MD

Welcoming Dr. Howard Hochster to Rutgers Cancer Institute and RWJBarnabas Health

Further enhancing a commitment to cutting-edge clinical research efforts, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are welcoming Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials and early phase cancer drugs. Dr. Hochster, who arrived earlier this month, is assuming the role of associate director for clinical research and chief of gastrointestinal medical oncology at Rutgers Cancer Institute, as well as director of cancer clinical research for oncology services at RWJBarnabas Health.

Andrew M. Evens, DO, MSc, FACP

New Oncology Leader at Rutgers Cancer Institute and RWJBarnabas Health to Focus on Integrated Care

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have named Andrew M. Evens, DO, MSc, FACP, as a new oncology leader responsible for the delivery of integrated cancer care across both entities in servicing the region. Dr. Evens, whose clinical expertise is in hematologic malignancies, most recently was the director of the Cancer Center at Tufts Medical Center in Boston. He will facilitate the integration of multidisciplinary clinical programs including those focused on survivorship and palliative care among other responsibilities.

DNA data

Tumor Mutational Burden and Response to Immune Checkpoint Therapy

Rutgers Cancer Institute of New Jersey researchers in the Precision Medicine Program examined an association between mutational burden and response to immune checkpoint therapy and found that a mutational burden threshold exists in eight cancers that predict response to an immune checkpoint blockade. The work was published in the December 7, 2017, issue of JCO Precision Oncology.

Century for the Cure celebration

Ride On!

Celebrating a successful 13 years, riders, supporters and organizers of the annual Century for the Cure bike ride recently gathered to acknowledge more than $2.2 million in cumulative funds raised for research at Rutgers Cancer Institute, which included a check presentation for $276,000 from this year's event. Ride founder and cancer survivor Scott Glickman (pictured right) shared a special moment with his physician, Roger Strair, MD, PhD, chief of blood disorders at Rutgers Cancer Institute - who rides in the annual 100 mile trek - when they hung this year's 'team jersey' on the wall in the hematology/oncology clinic.